Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571283 | 0.86 | ITGB3 (0.65) | ITGB3ITGA2BTHRBMMP2SLC6A3 | |
| Leucine SCHEMBL4586599 | 0.84 | ITGB3 (0.56) | ITGB3ITGA2BTHRBMMP2LTA4H | |
| SCHEMBL16124585 | 0.84 | THRB (0.48) | ITGB3ITGA2BTHRBLTA4HPTGS2 | |
| SCHEMBL14677041 | 0.84 | CYP1A2 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL14677015 | 0.83 | CYP1A2 (0.42) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16124583 | 0.83 | THRB (0.47) | ITGB3ITGA2BTHRBLTA4H | |
| Lysine SCHEMBL1921517 | 0.82 | ITGB3 (0.60) | ITGB3ITGA2BTHRBMMP2LTA4H | |
| Tyrosine SCHEMBL3485476 | 0.82 | ITGB3 (0.60) | ITGB3ITGA2BTHRBMMP2LTA4H | |
| Lysine SCHEMBL4198912 | 0.81 | ITGB3 (0.53) | ITGB3ITGA2BTHRBMMP2LTA4H | |
| SCHEMBL578906 | 0.81 | SLC6A4 (0.53) | SLC6A4TAAR1SLC6A2SLC6A3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710084-A | Use of mGluR5 antagonists for the treatment of amphetamine addiction | 诺华股份有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-112533595-A | Method for treating substance abuse | 感知神经科学公司 | 2021-03-19 | — | — | CN | claimed |
| CN-110191706-A | The treatment method for treating lidocaine invalid illness and hypokalemia illness | 阿卡利德公司 | 2019-08-30 | — | — | CN | claimed |
| CN-110167562-A | DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC are directed to the protective effect for causing the drug of ion channel disease | 萨恩帕斯药物有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-106163514-B | Agent for preventing and treating attention deficit and hyperactivity disorder | 藤本株式会社 | 2019-07-19 | — | — | CN | claimed |
| CN-109843331-A | Protective effects of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs causing ion channel diseases | 萨恩帕斯药物有限公司 | 2019-06-04 | — | — | CN | claimed |
| CN-103221535-A | Use of adenosine receptor signaling to modulate blood brain barrier permeability | UNIV CORNELL | 2013-07-24 | — | — | CN | claimed |
| CN-118338916-A | Multifunctional compounds for use in medical imaging and therapy | 安特络手术解决方案公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-112964625-B | Cell population analysis | 英国质谱公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118121577-A | Method for treating substance abuse | 感知神经科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117529665-A | Amphetamine carbamate compounds and methods | 诺芬药品公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-111699250-B | Carboxylesterase polypeptides for amide coupling | 科德克希思公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117295710-A | MDMA enantiomer | 思维医学股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | ITGB3 2842/4885ITGA2B 3373/4885SLC6A4 25/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | ITGB3 2591/4885ITGA2B 2640/4885SLC6A4 67/4885 |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | DNPEP, OGFR, OPRL1 | ITGB3 2428/4885ITGA2B 2529/4885SLC6A4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.